---
layout: default
title: Imatinib Mesylate
parent: 僅模型預測 (L5)
nav_order: 201
evidence_level: L5
indication_count: 0
---

# Imatinib Mesylate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Imatinib Mesylate: Repurposing Evaluation — No TxGNN Predictions Available

---

## One-Sentence Summary

Imatinib mesylate is a targeted tyrosine kinase inhibitor with a well-established role in oncology, most widely recognised for its use in chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). This Evidence Pack, however, contains **no TxGNN predicted indications**, **no SAHPRA registration records**, and **no safety data**, which means a full repurposing evaluation cannot be completed at this time. A **Hold** decision is recommended until the critical data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not captured in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | Unable to assess |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why a Prediction Cannot Be Assessed Yet

This Evidence Pack did not return any TxGNN predicted indications for imatinib mesylate. Without a model-generated candidate disease, no mechanistic bridge between a known indication and a new target condition can be formally evaluated.

Detailed mechanism of action data was not provided in this Evidence Pack. From published pharmacological literature, imatinib mesylate is known to selectively inhibit the BCR-ABL, c-Kit, and PDGF receptor (PDGFR) tyrosine kinases. This multi-kinase inhibitory profile is the basis for its use in haematological malignancies and solid tumours driven by oncogenic kinase signalling. Once MOA data is retrieved from DrugBank and TxGNN predictions are generated, this mechanistic profile could support repurposing into several kinase-driven disease contexts.

Until the pipeline is run successfully and indications are predicted, the repurposing rationale remains speculative and cannot be responsibly presented to clinicians.

---

## Cytotoxicity

Imatinib mesylate belongs to the targeted antineoplastic class (tyrosine kinase inhibitor). The following information reflects its established pharmacological classification.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — BCR-ABL / c-Kit / PDGFR tyrosine kinase inhibitor |
| Myelosuppression Risk | Moderate — neutropenia and thrombocytopenia are frequently reported class effects |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Full blood count (FBC) with differential, liver function tests (LFTs), renal function, body weight and fluid retention |
| Handling Protection | Standard cytotoxic handling precautions apply; oral tablet formulation requires care during dispensing |

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for imatinib mesylate is critically incomplete — the TxGNN model produced no predicted indications, no SAHPRA registration data was returned, and all safety fields were unresolved. Proceeding to clinical evaluation or procurement planning without these inputs would not be appropriate.

**To proceed, the following is needed:**

- **TxGNN predictions**: Re-run the KG and DL prediction pipeline with imatinib mesylate as the query drug to generate candidate repurposing indications
- **DrugBank linkage**: Map "IMATINIB MESYLATE" to its DrugBank entry to unlock MOA, category, and toxicity data
- **SAHPRA registration audit**: Confirm whether any imatinib products (e.g., Gleevec, generic imatinib) hold current SAHPRA approval; download and parse the PI for approved indications, warnings, and contraindications
- **Safety data extraction**: Retrieve key warnings, contraindications, and drug-drug interaction data from the SAHPRA PI and DrugBank interaction database
- **Evidence collection**: Once a predicted indication is confirmed, run ClinicalTrials.gov, PubMed, ICTRP, and PACTR collectors against the drug–disease pair
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

